RedHill Biopharma Presents New Talicia® and Movantik&#x

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the presentation of...

Related Keywords

United States , United Kingdom , Israel , Americans , Theresa Mallick Searle , Amber Fennell , Carolb Rockett , Darrenm Brenner , Bryan Gibbs , Redhill Biopharma , William Chey , Adi Frish , Marka Bush , Enoch Bortey , Jeremy Adler , Williamd Chey , Junes Almenoff , Saliln Pendse , Colinw Howden , National Cancer Institute , Redhill Biopharma Ltd , Nasdaq , Northwestern University Feinberg School Of Medicine , American College Of Gastroenterology , Company Annual Report On Form , End Results Program , Astrazeneca , Company Expanded Access Program , Prnewswire Redhill Biopharma Ltd , Centers For Disease , Gastrointestinal Physiology Laboratory , World Health Organization , Exchange Commission , University Of Tennessee Health Science Center , Corporate Business Development , Hill Biopharma , Scientific Meeting , American College , Tennessee Health Science , Associate Professor , Northwestern University Feinberg School , Functional Bowel , Rifabutin Dosing Provides Favorable Exposure , Physician Directed Treatment , Two Phase , Real World Prescribing , Accelerates Time , First Spontaneous Bowel Movement , Predictable Efficacy , Extreme Opioid Induced Constipation , Pooled Analysis , Achieved Rapid , Sustained Improvement , Opioid Induced Constipation , Two Pivotal Phase , Interstitial Nephritis , Private Securities Litigation Reform Act , Expanded Access Program , Annual Report , Disease Control , Systematic Review , Cell Biochem , Cancer Institute , Florence Consensus Report ,